Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market
Advertisement

Related Content

Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
Alexion Prepares To Launch Soliris In Japan Following Record NHI Price Listing Time
Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain
Japan Adds 12 Drugs To NHI Price List; Takeda Takes Four, Pfizer, Alexion Also Gain
Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
Advertisement
UsernamePublicRestriction

Register

SC074637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel